

This article was downloaded by:

On: 26 January 2011

Access details: *Access Details: Free Access*

Publisher *Taylor & Francis*

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Nucleosides, Nucleotides and Nucleic Acids

Publication details, including instructions for authors and subscription information:

<http://www.informaworld.com/smpp/title~content=t713597286>

MODIFIED DINUCLEOSIDE TETRAPHOSPHONATES, NEW POTENTIAL INHIBITORS OF HIV REVERSE TRANSCRIPTASE

E. A. Shirokova^a; A. L. Khandazhinskaya^a; Yu. S. Skoblov^a; L. Ye. Goryunova^b; R. S. Beabealashvili^b; A. A. Krayevsky^a

^a Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, Russia ^b Institute of Experimental Cardiology, National Cardiology Research Center, Moscow, Russia

Online publication date: 31 March 2001

To cite this Article Shirokova, E. A. , Khandazhinskaya, A. L. , Skoblov, Yu. S. , Goryunova, L. Ye. , Beabealashvili, R. S. and Krayevsky, A. A. (2001) 'MODIFIED DINUCLEOSIDE TETRAPHOSPHONATES, NEW POTENTIAL INHIBITORS OF HIV REVERSE TRANSCRIPTASE', *Nucleosides, Nucleotides and Nucleic Acids*, 20: 4, 1033 — 1036

To link to this Article: DOI: 10.1081/NCN-100002485

URL: <http://dx.doi.org/10.1081/NCN-100002485>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.informaworld.com/terms-and-conditions-of-access.pdf>

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

MODIFIED DINUCLEOSIDE TETRAPHOSPHONATES, NEW POTENTIAL INHIBITORS OF HIV REVERSE TRANSCRIPTASE

E. A. Shirokova,¹ A. L. Khandazhinskaya,¹ Yu. S. Skoblov,¹
L. Ye. Goryunova,² R. S. Beabealashvili,² and A. A. Krayevsky¹

¹Engelhardt Institute of Molecular Biology, Russian Academy of
Sciences, 32 Vavilov St., Moscow 117984, Russia

²Institute of Experimental Cardiology, National Cardiology Research
Center, 15A Cherepkovskaya St., Moscow, Russia

ABSTRACT


New γ -substituted analogues of dNTP were synthesized and their enzymatic stability and antiviral properties were evaluated.

INTRODUCTION

To inhibit HIV reproduction, nucleoside-based anti-HIV drugs must pass through the intracellular triphosphorylation cascade. The effectiveness of the triphosphate formation is very low (for AZT it is only about 0.1%), and it would be desirable to design phosphorylation-independent agents, which could directly inhibit the target HIV reverse transcriptase.

We recently reported the synthesis and some properties of nucleoside triphosphate mimetics bearing a cyclopentenyl residue as a glycone and a triphosphonate chain in place of a triphosphate one (**I**, **II**) [1]. They showed high stability in human blood serum, and some of them were selective inhibitors of DNA synthesis catalyzed by HIV reverse transcriptase. However, they are highly hydrophilic and may poorly penetrate through cell walls.

Dinucleoside 5',5'-tetraphosphates were demonstrated to be good substrates of some human and bacterial DNA polymerases and HIV reverse transcriptase. In




the latter case, the efficiency of incorporation into the DNA chain was close to that of the corresponding dNTPs [2]. It is worth mentioning that according to the TLC and HPLC data these dinucleotide analogues were much more lipophilic if compared with the corresponding triphosphates.

With this in mind, we synthesized, and evaluated enzymatic resistance of dinucleotide polyphosphate analogues (**IIIa–b**, **IVa–c**), which can be regarded as modified nucleoside triphosphates substituted at the γ -phosphate by a nucleotide residue. We also studied the inhibition by these compounds of pSG1 virus replication in rat Rat1 fibroblasts.

CHEMISTRY

The synthesis of target dinucleoside polyphosphonates **III** and **IV** as racemic mixtures was carried out using the corresponding monophosphonates **V** as key intermediates (Chart). Previously, for the preparation of diadenosine tetraphosphate analogues bearing β, β' -methylene or -dihalomethylene bridges, various procedures were used [3,4]. We carried out the coupling reaction with CDI as an activating agent. The formation of the side dimer (the corresponding dinucleoside α, α' -diphosphonate) was minimal when the molar excess of CDI was more than eight. Better yields of the target dinucleoside tetraphosphonates **III** and **IV** were obtained when the corresponding monophosphonates **V**, rather than diphosphonic acids, were activated. The target **III** and **IV** were also synthesized by coupling of triphosphonates **I** or **II** with the imidazolidine prepared from the corresponding **V**. For difluoromethylene analogues **IIIa** and **IVa**, the yields of the target products in both procedures were comparable (20–30% relative to the monophosphonate **V**), whereas dibromomethylene derivatives **IIIb** and **IVb** were only obtained from triphosphonates **Ib** and **IIb**.

We also synthesized dinucleoside triphosphate analogues (**VI**) and (**VII**) using a reaction of imidazolidine prepared from **V** and phosphoric acid under similar conditions.






Chart.

The structures of the compounds synthesized were confirmed by UV, ^1H and ^{31}P NMR spectroscopy and mass-spectrometry data [5].

ENZYMATIC STABILITY

The enzymatic stability of the guanine derivatives **IVa,c** was evaluated in human blood serum used as a model of a biologically active medium containing various types of hydrolyzing enzymes. The product composition was analysed by reverse-phase HPLC.

These dinucleotide derivatives demonstrated close enzymatic resistance, which was by one order of magnitude higher than that of natural dGTP, although twice lower than that of the corresponding difluoromethylene triphosphonate **IIa** (Table).

ANTIVIRAL ACTIVITY

Polyphosphonates **IIIa-b** and **IVa-b** were evaluated as antiviral agents in rat fibroblast Rat1 cell culture with the artificial virus containing Moloney murine

Table

Compounds	Half-Life Time, h
IVa	3
IVc	3
IIa	7
dGTP	0.3



leukemia virus reverse transcriptase. Their activity did not exceed 3–7 μM versus 7 nM for AZT. The activity of these polyphosphonates in HIV-infected cells is under investigation.

ACKNOWLEDGMENTS

The work was supported by ISTC, project 1244, and Russian Foundation for Basic Research, project no 99-04-48315.

REFERENCES

1. Shipitsyn, A. V.; Victorova L. S.; Shirokova, E. A.; Dyatkina, N. B.; Goryunova, L. Ye.; Beabealashvili, R. Sh.; Hamilton, C. J.; Roberts, S. M.; Krayevsky, A. A. *J. Chem. Soc. Perkin Trans 1*, **1999**, 1039–1050.
2. Victorova, L.; Sosunov, V.; Skoblov, A.; Shipitsyn, A.; Krayevsky, A. *FEBS Lett.*, **1999**, 453, 6–10.
3. Tarusova, N. B.; Osipova, T. I.; Purygin, P. P.; Yakimova, I. A. *Bioorg. Chem. (Russian)*, **1986**, 12, 404–407.
4. Guranovsky, A.; Starzynska, E.; Taylor, G. E.; Blackburn, G. M. *Biochem. J.*, **1989**, 262, 241–244.
5. ^{31}P NMR (if not stated otherwise, 163 MHz, D_2O , δ , proton decoupling): **IIIa**: 9.7 (m, $J_{\text{P}\alpha, \text{P}\beta}$ 33 Hz, P- α), –6.1 (m, $J_{\text{P}, \text{F}}$ 81 Hz, P- β); MS (m/e): 798.13 [M^+]; **IIIb**: ^{31}P NMR: 9.7 (d, J 23 Hz, P- α), –0.8 (d, P- β); MS (m/e) 920.23 [M^+]; **IVa**: ^{31}P NMR: 9.45 (d, J 20 Hz, P- α), –6.36 (m, $J_{\text{P}, \text{F}}$ 83 Hz, P- β); MS (m/e): 830.35 [M^+]; **IVb**: 9.7 (d, J 26 Hz, P- α), –0.8 (d, P- β); MS (m/e): 952.21 [M^+]; **IVc**: 8.8 (d, J 22 Hz, P- α), –22.7 (d, P- β); MS (m/e): 796.13 [M^+]; **VI**: 9.1 (d, J 24 Hz, P- α), –22.4 (t, P- β); MS (m/e): 684.17 [M^+]; **VII**: 9.1 (d, J 26 Hz, P- α), –22.3 (t, P- β); MS (m/e): 716.14 [M^+].



Request Permission or Order Reprints Instantly!

Interested in copying and sharing this article? In most cases, U.S. Copyright Law requires that you get permission from the article's rightsholder before using copyrighted content.

All information and materials found in this article, including but not limited to text, trademarks, patents, logos, graphics and images (the "Materials"), are the copyrighted works and other forms of intellectual property of Marcel Dekker, Inc., or its licensors. All rights not expressly granted are reserved.

Get permission to lawfully reproduce and distribute the Materials or order reprints quickly and painlessly. Simply click on the "Request Permission/Reprints Here" link below and follow the instructions. Visit the [U.S. Copyright Office](#) for information on Fair Use limitations of U.S. copyright law. Please refer to The Association of American Publishers' (AAP) website for guidelines on [Fair Use in the Classroom](#).

The Materials are for your personal use only and cannot be reformatted, reposted, resold or distributed by electronic means or otherwise without permission from Marcel Dekker, Inc. Marcel Dekker, Inc. grants you the limited right to display the Materials only on your personal computer or personal wireless device, and to copy and download single copies of such Materials provided that any copyright, trademark or other notice appearing on such Materials is also retained by, displayed, copied or downloaded as part of the Materials and is not removed or obscured, and provided you do not edit, modify, alter or enhance the Materials. Please refer to our [Website User Agreement](#) for more details.

[Order now!](#)

Reprints of this article can also be ordered at

<http://www.dekker.com/servlet/product/DOI/101081NCN100002485>